Cite
HARVARD Citation
Huang, C. et al. (2022). IDF21-0102 RANKL inhibitor Denosumab protects against glucolipotoxicity-induced β-cell dysfunction and apoptosis. Diabetes research and clinical practice. p. . [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Huang, C. et al. (2022). IDF21-0102 RANKL inhibitor Denosumab protects against glucolipotoxicity-induced β-cell dysfunction and apoptosis. Diabetes research and clinical practice. p. . [Online].